Is Viridian Therapeutics Inc (VRDN) overvalued? · rev $425.0K
Viridian Therapeutics Inc (VRDN) is a biotechnology company listed on US.
This page asks whether Viridian Therapeutics Inc (VRDN) looks expensive on cached numbers — not a short thesis.
Latest reported VRDN revenue for 2026-06-30 was $425.0K. Net income was -$232.0M. VRDN currently screens at market cap $1.39B.
VRDN currently screens at market cap $1.39B. A high multiple can be growth prepaid or a bubble. The filing has to explain the gap.
If the next VRDN 8-K cuts growth or raises capex, this “expensive” read gets worse. Until then the SEC page is the source.
Not investment advice. Use the VRDN stock page for the full model, not this heading.
Not investment advice.